keyword
MENU ▼
Read by QxMD icon Read
search

migraine prophylaxis

keyword
https://www.readbyqxmd.com/read/29280408/optimizing-the-long-term-management-of-chronic-migraine-with-onabotulinumtoxina-in-real-life
#1
Cristina Tassorelli, Gioacchino Tedeschi, P Sarchielli, Luigi Alberto Pini, Licia Grazzi, Pierangelo Geppetti, Marina De Tommaso, Marco Aguggia, P Cortelli, Paolo Martelletti
Management of chronic migraine is challenging. OnabotulinumtoxinA (OBT-A) is the only medication licensed for prevention of chronic migraine, and has been widely adopted in clinical practice. Limited data is available on its long-term use. Areas covered: Data from controlled trials are combined with available data on the long-term use of OBT-A in real-life studies, with information obtained in a recent survey among Italian headache centers, and the clinical experience of the authors. Six areas were identified as relevant to patients with chronic migraine: 1) definition of responders to OBT-A; 2) management of responders to OBT-A; 3) optimal timing of prophylaxis with OBT-A; 4) position of OBT-A in prevention of chronic migraine; 5) management of medication overuse, and 6) patient education...
December 27, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/29276263/calcitonin-gene-related-peptide-receptor-antagonists-for-migraine-prophylaxis
#2
Scot Walker
Migraine is a common disorder affecting 12% of the U.S. POPULATION: Prophylaxis is recommended for patients who experience frequent migraines. Because current drugs used for prophylaxis are not 100% effective and cause adverse effects that affect compliance, new strategies have been studied to prevent headaches. One new pharmacologic strategy is to use an inhibitor of the calcitonin gene-related peptide (CGRP). As a class, the CGRP receptor inhibitors have reduced monthly migraine days and are well tolerated...
June 2017: Hospital Pharmacy
https://www.readbyqxmd.com/read/29238692/migraine-related-vertigo
#3
Vithal D Udagatti, Rajendran Dinesh Kumar
Migraine related vertigo (MRV) is largely accepted in the vestibular community and probably represents the second most common cause of vertigo after benign positional vertigo by far exceeding Meniere's disease. The data on vestibular migraine management is still relatively poor, despite its enormous importance in daily practice. A 55-year old male presented with history of giddiness, imbalance, sweating and sensation of nausea with severe pulsating headache of one day duration. Ear, Nose and Throat examination was normal...
December 2017: Indian Journal of Otolaryngology and Head and Neck Surgery
https://www.readbyqxmd.com/read/29221971/preventive-treatment-with-lomerizine-increases-cerebral-blood-flows-during-the-interictal-phase-of-migraine
#4
Ken Ikeda, Joe Aoyagi, Sayori Hanashiro, Masahiro Sawada, Maya Kyuzen, Harumi Morioka, Junya Ebina, Junpei Nagasawa, Masaru Yanagihashi, Yuichi Ishikawa, Ken Miura, Kiyoko Murata, Takanori Takazawa, Kiyokazu Kawabe, Yasuo Iwasaki
BACKGROUND: Changes in regional cerebral blood flow (rCBF) were reported in migraineurs. However, little is known how preventive medications of migraine can influence rCBF. Lomerizine, a calcium channel blocker, has been used for migraine prophylaxis in Japan. We examined rCBF after lomerizine treatment. SUBJECTS AND METHODS: Migraine was diagnosed according to the criteria of the International Classification of Headache Disorders, Third Edition beta. Migraine subtype was classified into migraine with aura (MA) and migraine without aura (MO)...
December 5, 2017: Journal of Stroke and Cerebrovascular Diseases: the Official Journal of National Stroke Association
https://www.readbyqxmd.com/read/29212383/menstrual-migraine-a-review-of-current-and-developing-pharmacotherapies-for-women
#5
G Allais, Giulia Chiarle, Silvia Sinigaglia, Chiara Benedetto
Migraine is one of the most common neurological disorders in the general population. It affects 18% of women and 6% of men. In more than 50% of women migraineurs the occurrence of migraine attacks correlates strongly with the perimenstrual period. Menstrual migraine is highly debilitating, less responsive to therapy, and attacks are longer than those not correlated with menses. Menstrual migraine requires accurate evaluation and targeted therapy, that we aim to recommend in this review. Areas covered: This review of the literature provides an overview of currently available pharmacological therapies (especially with triptans, anti-inflammatory drugs, hormonal strategies) and drugs in development (in particular those acting on calcitonin gene-related peptide) for the treatment of acute migraine attacks and the prophylaxis of menstrual migraine...
December 12, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29204191/onabotulinumtoxina-in-the-treatment-of-patients-with-chronic-migraine-clinical-evidence-and-experience
#6
REVIEW
Chia-Chun Chiang, Amaal J Starling
Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4-2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, using a standardized injection protocol, was approved by the US Food and Drug Administration in 2010 for the treatment of chronic migraine. The approval was made based on results from two large, randomized, double-blind placebo-controlled trials: the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials...
December 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/29171146/onabotulinumtoxina-in-chronic-migraine-predictors-of-response-a-prospective-multicentre-descriptive-study
#7
Clara Domínguez, Patricia Pozo-Rosich, Marta Torres-Ferrús, Natalia Hernández-Beltrán, Carmen Jurado-Cobo, Carmen González-Oria, Sonia Santos, María José Monzón, Germán Latorre, Luis Carlos Álvaro, Ana Gago, Mercedes Gallego, Vicente Medrano, Mariano Huerta, Jessica García-Alhama, Roberto Belvís, Yago Leira, Rogelio Leira
BACKGROUND: OnabotulinumtoxinA is a treatment specifically approved for the prophylaxis of chronic migraine in adults. The aim of this study was to assess the effectiveness of OnabotulinumtoxinA in chronic migraine after 1 year of treatment in the real-life setting and to identify clinical predictors of outcome. METHODS: We designed a prospective multicentre study performed in 13 Hospitals in Spain. Patients underwent a complete medical history and examination. They received treatment with OnabotulinumtoxinA every 12 weeks over a year...
November 24, 2017: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/29131326/magnesium-in-migraine-prophylaxis-is-there-an-evidence-based-rationale-a-systematic-review
#8
REVIEW
Alexander von Luckner, Franz Riederer
OBJECTIVE: The primary objective was to systematically evaluate the existing evidence base on magnesium in migraine prophylaxis. METHODS: The search for clinical trials published from 1990 to 2016 was separately conducted by AvL and FR using standard search terms as well as MeSh terms on PubMed and EMBASE. Randomized, double-blind, placebo-controlled trials investigating prophylactic magnesium administration in migraineurs aged 18-65 were considered eligible. In a mutual effort, the studies found were sorted and analyzed under consideration of the guidelines for controlled trials for drugs in migraine by the International Headache Society and using predefined eligibility criteria...
November 13, 2017: Headache
https://www.readbyqxmd.com/read/29116598/cgrp-monoclonal-antibodies-for-migraine-rationale-and-progress
#9
Hsiangkuo Yuan, Clinton G Lauritsen, Eric A Kaiser, Stephen D Silberstein
Calcitonin gene-related peptide (CGRP), a neuropeptide abundant in the trigeminal system and widely expressed in both the peripheral and central nervous systems, has recently emerged as a promising target for migraine management. While known as a potent arterial vasodilator, the role of CGRP in migraine is likely mediated by modulating nociception and sustaining neurogenic inflammation that leads to further peripheral and central pain sensitization. Functional blockade of CGRP, which involves either CGRP receptor antagonists or monoclonal antibodies (mAbs) to CGRP or its receptor, has recently shown clinical efficacy in migraine management...
November 7, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29089894/safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-the-cgrp-binding-monoclonal-antibody-ly2951742-galcanezumab-in-healthy-volunteers
#10
David Monteith, Emily C Collins, Corinne Vandermeulen, Anne Van Hecken, Eyas Raddad, Joel C Scherer, David Grayzel, Thomas J Schuetz, Jan de Hoon
Background: Calcitonin gene-related peptide (CGRP) is pivotal in the pathophysiology of migraine headaches and represents a promising target for migraine treatment. The humanized monoclonal antibody galcanezumab (LY2951742) binds to CGRP and may be effective in migraine prophylaxis. Objectives: The primary objective was to evaluate the safety and tolerability of single and multiple doses of galcanezumab in humans. Secondary objectives included assessing the pharmacokinetics and evaluating target engagement...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29076422/the-prophylactic-use-of-antiepileptic-drugs-in-patients-scheduled-for-neurosurgery
#11
Barbara Miziak, Kinga Borowicz-Reutt, Radoslaw Rola, Barbara Blaszczyk, Miroslaw Czuczwar, Stanislaw J Czuczwar
Antiepileptic drugs (AEDs) possess diverse mechanisms of action - enhancement of GABA-mediated events, inhibition of glutamate-mediated excitation, blockade of voltage-dependent sodium or calcium channels being the most frequently shared. They are not only used for the symptomatic management of epilepsy but in the treatment of psychiatric or neurologic disorders (e.g. bipolar disorder, neuropathic pain, prophylaxis of migraine). Generally, this group of drugs is also widely used in neurosurgery patients for the prevention of seizure activity and their effectiveness in this regard has been evaluated in this review...
October 27, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29075232/the-efficacy-of-venlafaxine-flunarizine-and-valproic-acid-in-the-prophylaxis-of-vestibular-migraine
#12
Fenye Liu, Tianbao Ma, Xiaolin Che, Qirong Wang, Shudong Yu
BACKGROUND: Different types of medications are currently used in vestibular migraine (VM) prophylaxis, although recommendations for use are generally based on expert opinion rather than on solid data from randomized trials. We evaluated the efficacy and safety of venlafaxine, flunarizine, and valproic acid in a randomized comparison trial for VM prophylaxis. METHODS: Subjects were randomly allocated to one of three groups (venlafaxine group, flunarizine group, and valproic acid group)...
2017: Frontiers in Neurology
https://www.readbyqxmd.com/read/29065085/resolution-of-persistent-post-stapedotomy-vertigo-with-migraine-prophylactic-medication
#13
Omid Moshtaghi, Hossein Mahboubi, Yarah M Haidar, Ronald Sahyouni, Harrison W Lin, Hamid R Djalilian
OBJECTIVE: To describe persistent post-stapedotomy vertigo (PSV) and its treatment using migraine prophylaxis. PATIENTS: A retrospective review of all patients with persistent PSV spanning 10 years at a tertiary academic hospital was performed. Patients who experienced persistent vertigo for a minimum of 3 months after surgery were included. Those with possible perilymph fistula, long prosthesis, and benign paroxysmal positional vertigo were excluded. INTERVENTIONS: All patients received instructions on migraine dietary and lifestyle changes and Vitamin B2 and magnesium...
December 2017: Otology & Neurotology
https://www.readbyqxmd.com/read/29050521/glutamate-receptor-antagonists-with-the-potential-for-migraine-treatment
#14
REVIEW
Anna Ferrari, Cecilia Rustichelli, Carlo Baraldi
Preclinical, clinical, and other (e.g., genetic) evidence support the concept that migraine susceptibility may at least partially result from a glutamatergic system disorder. Therefore, the receptors of the glutamatergic system are considered relatively new targets for investigational drugs to treat migraine. Investigational and established glutamate receptor antagonists (GluRAs) have been shown to possess antinociceptive properties in preclinical models of trigeminovascular nociception and have been evaluated in clinical trials...
December 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29042000/nociceptive-blink-reflex-habituation-biofeedback-in-migraine
#15
M de Tommaso, M Delussi
Reduced habituation of the nociceptive blink reflex (NBR) is considered a trait marker for genetic predisposition to migraine. In this open-label randomized controlled study, we aimed to test the efficacy of a biofeedback training based on learning of habituation of the NBR (NBR biofeedback) compared with pharmacological (topiramate) treatment and NBR biofeedback plus topiramate treatment in a cohort of migraine without aura patients eligible for prophylaxis. Thirty-three migraine patients were randomly assigned to three months of treatment with: 1) NBR biofeedback, 2) NBR biofeedback plus topiramate 50 mg (b...
July 2017: Functional Neurology
https://www.readbyqxmd.com/read/29033605/onabotulinum-toxin-a-in-the-treatment-of-chronic-migraine-patient-selection-and-special-considerations
#16
REVIEW
Piero Barbanti, Patrizia Ferroni
Discovered by serendipity, onabotulinum toxin A (BoNT-A) is the only US Food and Drug Administration-approved treatment for the prevention of chronic migraine (CM), one of the most disabling and burdensome human conditions. Its efficacy, safety and tolerability, proved by the largest and longest migraine therapeutic trial (the Phase III Research Evaluating Migraine Prophylaxis Therapy program [PREEMPT]), have been replicated by various real-life studies also in the presence of medication overuse. The benefit of BoNT-A prophylaxis is likely due to its ability to counteract peripheral and central nociceptive sensitization through reversible chemical denervation of pericranial sensitive afferents...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/29020807/recognizing-the-role-of-cgrp-and-cgrp-receptors-in-migraine-and-its-treatment
#17
Lars Edvinsson, Karin Warfvinge
Premise The brain and the sensory nervous system contain a rich supply of calcitonin gene-related peptide (CGRP) and CGRP receptor components. Clinical studies have demonstrated a correlation between CGRP release and acute migraine headache that led to the development of CGRP-specific drugs that either abort acute attacks of migraine (gepants) or are effective as prophylaxis (antibodies). However, there is still much discussion concerning the site of action of these drugs. Problem Here we describe the most recent data related to CGRP in the trigeminal ganglion and its connections to the CNS, putative key regions involved in migraine pathophysiology...
January 1, 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/29017164/aspirin-prophylaxis-for-migraine-with-aura-an-observational-case-series
#18
Wendy E Turk, Anouk Uiterwijk, Raphaël Pasmans, Vera Meys, Cenk Ayata, Peter J Koehler
No abstract text is available yet for this article.
October 10, 2017: European Neurology
https://www.readbyqxmd.com/read/28990418/redox-mechanisms-in-migraine-novel-therapeutics-and-dietary-interventions
#19
Patrizia Ferroni, Piero Barbanti, David Della-Morte, Raffaele Palmirotta, Emilio Jirillo, Fiorella Guadagni
SIGNIFICANCE: Migraine represents the third most prevalent and the seventh most disabling human disorder. Approximately 30% of migraine patients experience transient, fully reversible, focal neurological symptoms (aura) preceding the attack. Recent Advances: Awareness of the hypothesis that migraine actually embodies a spectrum of illnesses-ranging from episodic to chronic forms-is progressively increasing and poses novel challenges for clarifying the underlying pathophysiological mechanisms of migraine as well as for the development of novel therapeutic interventions...
November 21, 2017: Antioxidants & Redox Signaling
https://www.readbyqxmd.com/read/28967118/a-review-of-migraine-prophylaxis-and-acute-treatment-patterns-among-commercially-insured-patients-in-the-united-states
#20
Lynda J Krasenbaum
No abstract text is available yet for this article.
October 2017: Headache
keyword
keyword
111314
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"